ID
38934
Beschreibung
Study ID: 111364 Clinical Study ID: 111364 Study Title: A 28-Day, Polysomnographic and subjective assessment of Vestipitant (15mg/day) for the treatment of Primary Insomnia in adult Outpatients Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00992160 Clinicaltrials.gov Links: https://clinicaltrials.gov/ct2/show/NCT00992160 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Vestipitant, Placebo Trade Name: N/A Study Indication: Primary Insomnia, Sleep Disorders This phase II, placebo-controlled, double-blind trial studies the polysomnographic and subjective effect of the neurokinin (NK1) antagonist vestipitant (15mg/day at bedtime) for the treatment of primary insomnia in adult outpatients over a period of four weeks. The study consists of a clinical Screening Visit (Visit 1), up to 21 days before investigational product/placebo initiation, two screening polysomnographies (Visits 2 and 3), followed by a placebo run-in until Visit 4, at which the subject is randomized to vestipitant or placebo, taken every night for 28 days. On Day 1 and 2 (Visits 4 and 5), polysomnographies are performed. Visit 6 is a safety visit on Day 15. On Day 27 and 28, Visits 7 and 8 are performed, which again include polysomnography studies. Subjects then undergo a 7 to 10 day placebo run-out period and have Day 7 and Day 14 Follow-Up Visit (Visits 9 and 10). The purpose of this form is to record whether consent for PGx Pharmacogenetic Research has been withdrawn, and whether the sample was requested to be destroyed.
Link
https://clinicaltrials.gov/ct2/show/NCT00992160
Stichworte
Versionen (1)
- 14.11.19 14.11.19 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
14. November 2019
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Polysomnographic Assessment of Vestipitant for the Treatment of Primary Insomnia NCT00992160
Pharmacogenetic Research Consent Withdrawal
- StudyEvent: ODM
Beschreibung
Withdrawal of consent for PGx (DNA) sample destruction
Alias
- UMLS CUI-1
- C1707492
- UMLS CUI-2
- C0031325
- UMLS CUI-3
- C0035168
- UMLS CUI-4
- C1948029
- UMLS CUI-5
- C0444245
Beschreibung
If yes, record date
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C0031325
- UMLS CUI [1,3]
- C0035168
Beschreibung
If applicable
Datentyp
date
Alias
- UMLS CUI [1,1]
- C1707492
- UMLS CUI [1,2]
- C0031325
- UMLS CUI [1,3]
- C0035168
- UMLS CUI [1,4]
- C0011008
Beschreibung
If yes, record reason below
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1272683
- UMLS CUI [1,2]
- C1948029
- UMLS CUI [1,3]
- C0444245
Beschreibung
If other reason, specify below
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0566251
- UMLS CUI [1,2]
- C1272683
- UMLS CUI [1,3]
- C1948029
- UMLS CUI [1,4]
- C0444245
Beschreibung
if applicable
Datentyp
text
Alias
- UMLS CUI [1,1]
- C1521902
- UMLS CUI [1,2]
- C3840932
- UMLS CUI [1,3]
- C1272683
- UMLS CUI [1,4]
- C1948029
- UMLS CUI [1,5]
- C0444245
Ähnliche Modelle
Pharmacogenetic Research Consent Withdrawal
- StudyEvent: ODM
C2985720 (UMLS CUI [2])
C0031325 (UMLS CUI-2)
C0035168 (UMLS CUI-3)
C1948029 (UMLS CUI-4)
C0444245 (UMLS CUI-5)
C0031325 (UMLS CUI [1,2])
C0035168 (UMLS CUI [1,3])
C0031325 (UMLS CUI [1,2])
C0035168 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C1948029 (UMLS CUI [1,2])
C0444245 (UMLS CUI [1,3])
C1272683 (UMLS CUI [1,2])
C1948029 (UMLS CUI [1,3])
C0444245 (UMLS CUI [1,4])
C3840932 (UMLS CUI [1,2])
C1272683 (UMLS CUI [1,3])
C1948029 (UMLS CUI [1,4])
C0444245 (UMLS CUI [1,5])